Clinical Trial Detail

NCT ID NCT01978236
Title Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Dabrafenib

Age Groups: adult senior

Additional content available in CKB BOOST